Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project
Alessandro Maloberti,C. Giannattasio,M. Bombelli,G. Desideri,A. F. G. Cicero,M. L. Muiesan,E. A. Rosei,M. Salvetti,A. Ungar,G. Rivasi,R. Pontremoli,F. Viazzi,R. Facchetti,C. Ferri,B. Bernardino,F. Galletti,L. D’Elia,P. Palatini,E. Casiglia,V. Tikhonoff,C. M. Barbagallo,P. Verdecchia,S. Masi,F. Mallamaci,M. Cirillo,M. Rattazzi,P. Pauletto,P. Cirillo,L. Gesualdo,A. Mazza,M. Volpe,G. Tocci,G. Iaccarino,P. Nazzaro,L. Lippa,G. Parati,R. Dell’Oro,F. Quarti-Trevano,G. Grassi,A. Virdis,C. Borghi,
DOI: https://doi.org/10.1007/s40292-020-00368-z
2020-03-10
Abstract:The latest European Guidelines of Arterial Hypertension have officially introduced uric acid evaluation among the cardiovascular risk factors that should be evaluated in order to stratify patient's risk. In fact, it has been extensively evaluated and demonstrated to be an independent predictor not only of all-cause and cardiovascular mortality, but also of myocardial infraction, stroke and heart failure. Despite the large number of studies on this topic, an important open question that still need to be answered is the identification of a cardiovascular uric acid cut-off value. The actual hyperuricemia cut-off (> 6 mg/dL in women and 7 mg/dL in men) is principally based on the saturation point of uric acid but previous evidence suggests that the negative impact of cardiovascular system could occur also at lower levels. In this context, the Working Group on uric acid and CV risk of the Italian Society of Hypertension has designed the Uric acid Right for heArt Health project. The primary objective of this project is to define the level of uricemia above which the independent risk of CV disease may increase in a significantly manner. In this review we will summarize the first results obtained and describe the further planned analysis.
English Else